Management of a high-risk surgery with emicizumab and factor viii in a child with a severe hemophilia a and inhibitor

HIGHLIGHTS

• who: THIEME and colleagues from the Bretagne, France have published the article: Management of a High-Risk Surgery with Emicizumab and Factor VIII in a Child with a Severe Hemophilia A and Inhibitor, in the Journal: (JOURNAL) of November/15,/2020
• what: The phase III randomized studies have shown more efficient prophylaxis of this subcutaneous administered drug in these patients compared with recombinant FVIIa (rFVIIa) and activated prothrombin complex concentrates (aPCC).2 3 Nonetheless there are "real life" matters that need to be explored in this new era of managing patients such as surgery management . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.